Altimmune FY2029 EPS Forecast Decreased by HC Wainwright

Altimmune, Inc. (NASDAQ:ALT) – HC Wainwright decreased their FY2029 earnings per share (EPS) estimates for shares of Altimmune in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $1.26 for the year, down from their previous forecast of $1.30. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%.

A number of other research firms have also commented on ALT. UBS Group assumed coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. William Blair started coverage on Altimmune in a research report on Friday, February 28th. They set a “market perform” rating on the stock. Finally, Stifel Nicolaus assumed coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.83.

Altimmune Trading Down 4.0 %

ALT stock opened at $5.72 on Wednesday. Altimmune has a one year low of $5.28 and a one year high of $11.77. The firm has a 50-day moving average of $6.74 and a two-hundred day moving average of $7.18. The firm has a market capitalization of $440.52 million, a PE ratio of -3.69 and a beta of 0.87.

Institutional Investors Weigh In On Altimmune

Several institutional investors have recently made changes to their positions in the company. Larson Financial Group LLC acquired a new position in Altimmune in the third quarter worth approximately $31,000. SBI Securities Co. Ltd. acquired a new position in shares of Altimmune during the 4th quarter worth $45,000. Virtus ETF Advisers LLC bought a new position in shares of Altimmune during the 4th quarter valued at $60,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Altimmune in the 4th quarter valued at $72,000. Finally, Sunbelt Securities Inc. boosted its holdings in Altimmune by 356.8% in the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock worth $79,000 after purchasing an additional 8,470 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.